Health
Investigational Alzheimer’s drug reduces molecular markers of the disease – News-Medical.Net
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating…
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of…
Continue Reading
-
Business23 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business22 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News19 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business19 hours ago1 ASX dividend stock down 43% I’d buy right now